Cellectis SA reported a consolidated net loss attributable to shareholders of $41.3 million, or $0.41 per share, for the nine-month period ended September 30, 2025, compared to a net loss of $42.7 million, or $0.49 per share, for the same period in 2024. The period included a $5.8 million loss from fair value remeasurement of warrants issued to the European Investment Bank, a $16.7 million increase in foreign exchange loss, and a $7.5 million decrease in loss on fair value of investment in shares of Cibus, Inc. Cash inflows included $30.5 million from revenue, $7.1 million in interest from financial and cash-equivalent investments, and $2.9 million from credit VAT. Cash outflows included $35.5 million to suppliers, $32.4 million for wages, bonuses, and social expenses, $8.1 million for lease debt payments, $4.0 million repayment of the "PGE" loan, and $3.0 million for capital expenditures. Cellectis plans to focus its cash spending on developing its pipeline, including manufacturing and clinical development of lasme-cel, eti-cel, and other potential product candidates.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571630-en) on November 07, 2025, and is solely responsible for the information contained therein.
Comments